Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 201–300 of 761
Wulandari, N., Maifitrianti, M., Hasanah, F., Atika, S., & Putri, R. D. (2020) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_257_19 · Cited by 16
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Pantalone, K. M., Heller, C. G., Lajara, R., Lew, E., Li, X., DEX, T. A., & Kilpatrick, C. R. (2023) · Diabetes Spectrum · doi:10.2337/ds22-0064 · Cited by 19
Eid, S., O’Brien, P. D., Kretzler, K. H., Jang, D., Mendelson, F. E., Hayes, J. M., Carter, A., Zhang, H., Pennathur, S., Brosius, F. C., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202300354r · Cited by 16
A Systematic Review of the Hill-Bone Compliance to Blood Pressure Therapy Scale
Commodore-Mensah, Y. Y., Delva, S., Ogungbe, O., Smulcer, L. A., Rives, S., Himmelfarb, C. D., Kim, M. T., Bone, L., Levine, D., & Hill, M. N. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s412198 · Cited by 26
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes
Davison, N., Guthrie, N. L., Medland, S., Lupinacci, P. J., Nordyke, R. J., & Berman, M. A. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02752-2 · Cited by 16
“%) with the current standard of care (SoC) options resulting in high rates of morbidity and mortality [3].”
BackgroundSulis, P. M., Dambrós, B. F., Mascarello, A., Santos, A. R. S., Yunes, R. A., Nunes, R. J., Frederico, M. J. S., & Silva, F. R. M. B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27680 · Cited by 15
“Currently, diabetes therapy has limitations, and is based on the use of a combination of medications, which decreases patient adherence to treatment (Polonsky & Henry, 2016).”
BackgroundScarton, L. J., Velazquez, I., O’Neal, L. J., Iyerm, S., Cannady, T. K., Choate, A., Mitchell, C., & Wilkie, D. J. (2019) · Research in Nursing & Health · doi:10.1002/nur.21941 · Cited by 20
“Medication taking plays an important role in diabetes management and is important in achieving positive diabetes outcomes; however, medication taking continues to be a challenge for those managing T2D and can lead to deleterious outcomes (Polonsky & Henry, 2016).”
BackgroundOfori‐Asenso, R., Liew, D., Lalic, S., Mazidi, M., Magliano, D. J., Ademi, Z., Bell, J. S., & Ilomäki, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01077-3 · Cited by 19
Reminders for medication adherence in Type 2 diabetes management apps
Jiménez, G., Lum, E., Huang, Z., Theng, Y. L., Boehm, B. O., & Car, J. (2020) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1595 · Cited by 18
Garnero, T. L., Davis, N. J., Perez-Nieves, M., Hadjiyianni, I., Cao, D., Ivanova, J. I., & Peyrot, M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1457396 · Cited by 14
“tence in several chronic diseases, including diabetes [34].”
BackgroundInjection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Hearn, E. B., & Sherman, J. J. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0033 · Cited by 16
Silva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., Bernal-Ceballos, F., de la Torre-Saldaña, V., Galíndez-Fuentes, A. I., & Castillo‐Martínez, L. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.09.002 · Cited by 18
Lunghi, C., Zongo, A., Tardif, I., Demers, É., Diendere, J. D., & Guénette, L. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108566 · Cited by 16
Adherence to Non-Selective Beta Blockers for Prevention of Variceal Bleeding in Cirrhotic Patients
An, Y., Xu, X., Ren, T., Tong, Z., Romeiro, F. G., Mancuso, A., Guo, X., & Qi, X. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s326192 · Cited by 15
Boye, K. S., Shinde, S., Kennedy‐Martin, T., Robinson, S. J., & Thieu, V. T. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 14
Lajara, R., Heller, C. G., Pantalone, K. M., Lew, E., Li, X., DEX, T. A., & Kilpatrick, C. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14974 · Cited by 16
Hoopes, M. J., Angier, H. E., Raynor, L. A., Suchocki, A., Muench, J., Marino, M., Rivera, P., & Huguet, N. (2018) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocy095 · Cited by 18
“Failure to adhere to medication protocols leads to increased patient morbidity and mortality coupled with higher medical costs and increased utilization of medical resources.(7) Yet, studies have shown about 25% of prescriptions go unfilled.”
BackgroundJi, L., Li, L., Ma, J., Li, X., Li, D., Meng, B., Lu, W., Sun, J., Liu, Y., Takayanagi, G., et al. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.222 · Cited by 21
Medication adherence of diabetes mellitus patients in Indonesia: A systematic review
Pertiwi, M. V., Alfian, R., Nita, Y., & Athiyah, U. (2022) · Pharmacy Education · doi:10.46542/pe.2022.222.188193 · Cited by 40
Doya, I. F., Yahaya, J. J., Ngaiza, A. I., & Bintabara, D. (2023) · International Health · doi:10.1093/inthealth/ihad042 · Cited by 22
“13,17,18 Little data are available regarding prevalence and its factors associated with low medication adherence among patients with T2DM in Tanzania.”
BackgroundFiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
“12 These complications include macrovascular conditions such as coronary heart disease, stroke, peripheral arterial disease and heart failure, as well as micro-vascular conditions like diabetic kidney disease, retinopathy and peripheral neuropathy.”
Diabetes-Related Complications and Pancreatic Cancer Incidence in the Multiethnic Cohort
Farias, A. J., Wu, A. H., Porcel, J., Marchand, L. L., Wilkens, L. R., Monroe, K. R., Maskarinec, G., Pandol, S. J., & Setiawan, V. W. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa035 · Cited by 16
“Patients with a higher DCSI score may be less likely to take appropriately dosed medications than those without complications (37) and would therefore bias the observed results toward the null.”
ResultCherrington, A., Krause-Steinrauf, H. J., Bebu, I., Naik, A. D., Walker, E. A., Golden, S. H., & Gonzalez, J. S. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106366 · Cited by 14
Verma, M., Sharma, P., Chaudhari, A., Sharma, M., & Kalra, S. (2021) · Cureus · doi:10.7759/cureus.18489 · Cited by 14
Boye, K. S., Shinde, S., Kennedy-Martin, T., Robinson, S., & Thieu, V. T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s328583 · Cited by 18
“These individual treatment characteristics can impact medicationtaking behaviors among people with diabetes (PwD).(23) Medication taking can be viewed at the simplest level as three stages at which PwD exhibit different drug-taking behaviors.”
BackgroundTelehealth for the Management of Diabetes in Pregnancy
Zork, N. M. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01476-x · Cited by 19
Callan, J. A., Sereika, S. M., Cui, R., Tamres, L. K., Tarneja, M., Greene, B., Slyke, A. V., Wu, M., Lukac, G. R., & Dunbar‐Jacob, J. M. (2022) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106221133027 · Cited by 16
Zwane, J., Modjadji, P., Madiba, S., Moropeng, L., Mokgalaboni, K., Mphekgwana, P. M., Kengne, A. P., & Mchiza, Z. J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20105887 · Cited by 21
Nemlekar, P. M., Hannah, K. L., Green, C. R., & Norman, G. J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01529-8 · Cited by 14
“Adherence to diabetes medication is associated with improved glycemic control, lower healthcare utilization, reduced medical costs, and lower mortality rates [7, 8].”
BackgroundMeneghini, L., Blonde, L., Gill, J., Dauchy, A., Bacevicius, A., Strong, J. L., & Bailey, T. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14116 · Cited by 11
Jude, E. B., Trescolí, C., Emral, R., Ali, A., LUBWAMA, R. N., PALMER, K. D., Shaunik, A., Nanda, N., Raskin, P., & Peralta, F. G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14298 · Cited by 15
“Furthermore, premixed insulin regimens are strict, requiring either two or three daily injections based on carbohydrate intake estimation with each meal,(17) and people with diabetes are more likely to skip insulin injections if their treatment regimen includes multiple daily injections, interferes with their daily ac…”
BackgroundTamuhla, T., Dave, J. A., Raubenheimer, P. J., & Tiffin, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251303 · Cited by 18
Whooley, S., Briskin, T., Gibney, M. A., Blank, L. R., Bérubé, J., & Pflug, B. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0585-7 · Cited by 13
Adherence to metformin in adults with type 2 diabetes: a combined method approach
Syafhan, N. F., Donnelly, R., Harper, R., Harding, J., Mulligan, C., Hogg, A., Scott, M., Fleming, G. F., Scullin, C., Hawwa, A. F., et al. (2022) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-022-00457-5 · Cited by 14
Bedtime Prediction of Nocturnal Hypoglycemia in Insulin-Treated Type 2 Diabetes Patients
Kronborg, T., Hangaard, S., Hejlesen, O. K., Vestergaard, P., & Jensen, M. H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221141736 · Cited by 12
“11,12 The resultant fear of hypoglycemia further leads to reduced adherence to insulin 13 as patients may change behavior after hypoglycemic episodes including increased calorie intake and reduction or skipping of insulin doses.”
BackgroundMorelli, D., Rubinstein, F., Santero, M., Gibbons, L., Moyano, D. L., Nejamis, A., & Beratarrechea, A. G. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09082-7 · Cited by 20
Wang, X., Xiao, W. L., Liang, Z., Li, S., & Tang, Q. (2023) · Medicine · doi:10.1097/md.0000000000036308 · Cited by 14
Yıldırım, D., Yıldız, C. Ç., Ergin, E., & Özbay, İ. (2024) · International Journal of Nursing Practice · doi:10.1111/ijn.13248 · Cited by 13
MacDonald, C., Bennekou, M., Midtgaard, J., Langberg, H., & Lieberman, D. E. (2024) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108396 · Cited by 17
“69 Adherence rates to glucose-lowering medications vary significantly across studies ranging from 36% to 93% for oral hypoglycaemic agents depending on treatment duration, adherence definitions and population.”
Siddiqui, M. H., Khan, I. A., Moyeen, F., & Chaudhary, K. A. (2019) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2019/asjbccr.6149 · Cited by 13
““Drugs do not work in patients who do not take them” Charles Everette Koop (1916-2013)-Surgeon General of United States The results of the study, although not unexpected in setup like ours, were disappointing.”
BackgroundShields, B. M., Hattersley, A. T., & Farmer, A. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13865 · Cited by 15
“A wide range of factors have been shown to be associated with poor adherence to diabetes medications including clinical features (female sex, younger age, non-white ethnicity), other comorbidities such as depression,(2) the class of medication and other prescriptions (medications after first-line metformin,(4) total d…”
BackgroundResultYu, M., Wang, C., Lee, M., Ou, H., Cheng, P., Tu, S., Huang, J., Chen, J.-F., Hu, T., Hsu, C., et al. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.01.011 · Cited by 12
Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review
Tamborlane, W. V., & Shehadeh, N. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02642-7 · Cited by 12
“Furthermore, treatment adherence is a concern in younger people with diabetes [36], and while data are lacking specifically on GLP-1 RAs in this population, a study investigating adherence to GLP-1 RA in adults in the US, demonstrated that more than 50% of patients were non-adherent and 70.”
BackgroundMartin, M., Patterson, J., Allison, M., O’Connor, B. B., & Patel, D. K. (2021) · JMIR Diabetes · doi:10.2196/24981 · Cited by 16
Chan, J. C. N., Mbanya, J. C., Chantelot, J., Shestakova, M. V., Ramachandran, A., ILKOVA, H. M., Deplante, L., Rollot, M., Melas‐Melt, L., Gagliardino, J. J., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14228 · Cited by 16
“Despite the large number of new therapies developed during the past two decades, only 30 – 40% of patients were at the recommended glycated hemoglobin (HbA 1c ) goal 7%, which had not improved over time in most surveys 2, 3 .”
BackgroundMnatzaganian, G., Lee, C., Cowen, G., Boyd, J., Varhol, R., Randall, S. M., & Robinson, S. (2024) · BMC Medicine · doi:10.1186/s12916-024-03698-0 · Cited by 19
“Non-compliance with long-term medication for conditions like diabetes, hypertension, and dyslipidaemia is not uncommon, leading to compromised health risks [45].”
BackgroundKumar, H., Abdulla, R. A., & Lalwani, H. (2021) · ATHENS JOURNAL OF HEALTH & MEDICAL SCIENCES · doi:10.30958/ajhms.8-2-2 · Cited by 14
Iqbal, M. Z., Iqbal, M. Z., Alqahtani, S. S., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1323102 · Cited by 11
“Effective management of diabetes and glycemic control relies significantly on physician adherence to prescribed guidelines, and patient compliance and adherence to medication regimens play a crucial role (6).”
BackgroundSimacek, K. F., Curran, C. J., Fenici, P., & García‐Sánchez, R. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s186801 · Cited by 14
“0) sex, n (%) Female 99 (67) 62 (55) 45 (45) 49 (49) 42 (42) 55 (55) Male 48 (32) 51 (45) 55 (55) 51 (51) 58 (58) 45 (45) Prefer to skip 1 (1) 0 0 0 0 0 education, n (%) high school graduate or less 23 (16) 35 (31) 75 (75) 42 (42) 48 (48) 41 (41) some college 55 (37) 45 (40) 4 (4) 12 (12) 22 (22) 33 (33) college gradu…”
Weinman, J. A., Ali, I., Hodgkinson, A., Canfield, M., & Jackson, C. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s219860 · Cited by 11
THE RELATIONSHIP BETWEEN SELF-EFICACY AND SELF-CARE IN TYPE 2 DIABETES MELLITUS PATIENTS
Wahyuni, A., & Ramayani, D. (2020) · The Malaysian Journal of Nursing · doi:10.31674/mjn.2020.v11i03.011 · Cited by 15
Lobo, J. M., Kim, S. Y., Kang, H., Ocker, G., McMurry, T. L., Balkrishnan, R., Anderson, R. T., McCall, A. L., Benitez, J. A., & Sohn, M. (2020) · Diabetes Care · doi:10.2337/dc19-0874 · Cited by 12
Keegan, C. N., Johnston, C. A., Cardenas, V. J., & Vaughan, E. M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030121 · Cited by 10
Self-Care Management Practices of Diabetic Patients Type 2 in Saudi Arabia
Alotaibi, B. (2020) · Open Journal of Nursing · doi:10.4236/ojn.2020.1011071 · Cited by 11
Hirsch, J. D., Kong, N., Nguyen, K. T., Cadiz, C. L., Zhou, C., Bajorek, S. A., Bounthavong, M., & Morello, C. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179242 · Cited by 16
“It is estimated that over 45% of patients with type 2 diabetes fail to ever achieve glycemic control, which may be attributed in large part to poor medication adherence [2].”
BackgroundLewing, B., Abughosh, S., Lal, L. S., Essien, E. J., Sansgiry, S., & Sansgiry, S. S. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100046 · Cited by 14
Sultan, S., El-Hourani, M., Rondeau, É., & Garnier, N. B. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s177624 · Cited by 14
“For social environment, normative pressure and social influence are examples.(12,13) An example of practical factor refers to the type of delivery device, with the use of pens consistently yielding higher levels of adherence than syringe in all reviewed studies.”
Aleppo, G., Parkin, C. G., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., Umpierrez, G. E., Forlenza, G. P., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0196 · Cited by 11
Young‐onset type 2 diabetes—Epidemiology, pathophysiology, and management
Luk, A. O. Y., Wu, H., Fan, Y., Fan, B., Chun Kwan, O., & Chan, J. C. N. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70081 · Cited by 14
“However, unless these young patients can establish trust in their health-care team for advice and support, their competing priorities — such as jobs, families, and social life — may result in nonadherence and missed appointments 186 .”
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“Although once-daily oral small-molecule medications are often the preferred first-line choice, adherence issues can still happen, especially in asymptomatic conditions [228,229].”
Majeed, U., Aftab, M. F., Baloch, D. M., Ahmed, S., Yusuf, I. M., Hasan, M. A., & Qureshi, M. S. (2021) · Journal of Religion and Health · doi:10.1007/s10943-021-01431-2 · Cited by 13
Diabetes and current Indian scenario: A narrative review
Muralidharan, S. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_93_23 · Cited by 10
Managing drug therapy-related problems and assessment of chronic diabetic wounds
Mahendran, M. I. M. S., Gopalakrishnan, V., Saravanan, V., Ramasamy, D., Jothimani, P., Balasubramanian, M., Singh, A. K., & Vaithianathan, R. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2414893 · Cited by 13
“Since patients’ non-compliance with prescribed diabetes medication presents a challenge to diabetes management, identifying the reasons behind this noncompliance is a first step toward a sensible and successful intervention strategy 51–53 .”
Jones, J., Goins, R. T., Schure, M. B., Winchester, B., & Bradley, V. (2019) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721719894889 · Cited by 12
Diabetes, Therapeutic Inertia, and Patients’ Medication Experience
Bzowyckyj, A. S., & Begert, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0019 · Cited by 11
Kalirai, S., Ivanova, J. I., Perez‐Nieves, M., Stephenson, J. J., Hadjiyianni, I., Grabner, M., Pollom, R. D., Geremakis, C. M., Reed, B. L., & Fisher, L. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s237948 · Cited by 9
Use of Interventions to Overcome Medication Non-Adherence
Saha, S. K., Adhikary, A., Jha, A. K., & Mehta, V. K. (2021) · International Journal of Asian Business and Information Management · doi:10.4018/ijabim.20210701.oa18 · Cited by 10
Schürmann, D., Rudd, D. J., Schaeffer, A., Lepeleire, I. D., Friedman, E. J., Robberechts, M., Zhang, S., Liu, Y., Kandala, B., Keicher, C., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002834 · Cited by 11
Farooqi, M. H., Abdelmannan, D. K., AlBuflasa, M., Hamed, M. A. A., Xavier, M., Cadiz, T. J. S., & Nawaz, F. A. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/6286574 · Cited by 13
“Poor adherence to medication and BG monitoring schedules is a strong independent predictor of inadequate glycemic control in people with T2DM [42].”
Fink, A., Dörre, A., Demuth, I., & Doblhammer, G. (2022) · BMC Neurology · doi:10.1186/s12883-022-02682-6 · Cited by 12
H., A. H. V. A., V, & Prabhu, S. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2375 · Cited by 11
Umeukeje, E. M., Washington, J. T., & Nicholas, S. B. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.05.004 · Cited by 14
A Systematic Review of Independent and Chain Pharmacies Effects on Medication Adherence
Nind, J., Smith, A. J., Scahill, S. L., & Marra, C. A. (2022) · Pharmacy · doi:10.3390/pharmacy10050124 · Cited by 20
GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
Romera, I., Santos, M. R., Artola, S., Fernández, C. S., & Conget, I. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02442-z · Cited by 12
“Also, weekly administration is available for GLP-1 RAs, which may be preferable to daily insulin and improve adherence to treatment [45, 46].”
BackgroundIs Continuous Glucose Monitoring a Tool, an Intervention, or Both?
Wright, E. E., & Subramanian, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0025 · Cited by 13
“11 More importantly, they may fail to detect potentially life-threatening situations such as hypoglycemia as shown in Figure 2.”
Ambient heat and diabetes hospitalizations: Does the timing of heat exposure matter?
Gao, D., Friedman, S., Hosler, A. S., Sheridan, S. C., Zhang, W., Yu, F., & Lin, S. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.169011 · Cited by 10
Müller, S., Wilke, T., Fuchs, A., et al. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s134924 · Cited by 10
Pereira, M. G., Pedras, S., Ferreira, G., & Machado, J. C. (2018) · Journal of Health Psychology · doi:10.1177/1359105318780505 · Cited by 12
“Adherence to medication has been associated with stronger beliefs about the need of medicines and weaker beliefs about concerns with medicines and its harmful effects in general, in T2DM patients (Polonsky and Henry, 2016; Sweileh et al., 2014).”
BackgroundPrevalence of Universal Medication Schedule prescribing and links to adherence
Wolf, M. S., Taitel, M. S., Jiang, J., Curtis, L. M., Wismer, G. A., Wallia, A., & Parker, R. M. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz305 · Cited by 10
Ramachandran, B., Trinacty, C. M., Wharam, J. F., Duru, O. K., Dyer, W. T., Neugebauer, R. S., Karter, A. J., Brown, S. D., Marshall, C. J., Wiley, D. M., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06237-8 · Cited by 12
Kow, C. S., & Hasan, S. S. (2021) · British Journal of Pharmacy · doi:10.5920/bjpharm.836 · Cited by 10
“…such as hypertension, diabetes mellitus, cardiovascular diseases, and chronic respiratory diseases are at risk of medication non-adherence, even before the COVID-19 crises Critical Review Kow and Hasan (2021) BJPharm, 6(1), Article 836 2 (Abegaz et al., 2020; McQuaid, 2018; Polonsky & Henry, 2016).”
BackgroundSakai, R., Hashimoto, Y., Ushigome, E., Okamura, T., Hamaguchi, M., Yamazaki, M., Oda, Y., & Fukui, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12916 · Cited by 11
Ulrich, F. S., Napoli, N., Nielsen, M. F., & Burden, A. M. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70535 · Cited by 10
Hood, R. C., Borra, S., Fan, L., Pollom, R. D., Huang, A., & Chen, J. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.006 · Cited by 9
Kamat, T., Dang, A., Dang, D., & Rane, P. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_35_21 · Cited by 9
Khoiry, Q. A., Alfian, S. D., & Abdulah, R. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1072085 · Cited by 18
“At least 45% of treatment failures among DM patients are caused by low adherence to anti-diabetic medical treatments (12).”
BackgroundHirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
“76 This is particularly important given the relatively high rates of poor adherence and discontinuation of GLP-1RA therapy over time due to adverse events.”
Salama, H. M., & Saudi, R. A. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00587-0 · Cited by 13
“Moderate concerns about potential negative effects of medicines were also observed in other studies [27].”
ResultJi, L., Ma, J., Lu, W., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13389 · Cited by 9
Widayanti, A. W., Sigalingging, K. K., Dewi, F. P., & Widyakusuma, N. N. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s301501 · Cited by 11
“It has been suggested that decreasing the frequency of daily doses and using insulin pens instead of insulin vial may improve adherence.(37,39) However, in the context of Indonesia, the use of insulin pens may provide further burden related to accessibility and cost.”
BackgroundPopulation stratification in type 2 diabetes mellitus: A systematic review
Hodgson, S., Cheema, S., Rana, Z., Olaniyan, D., O’Leary, E., Price, H. C., & Dambha‐Miller, H. (2021) · Diabetic Medicine · doi:10.1111/dme.14688 · Cited by 11
Lewing, B., Sansgiry, S., Abughosh, S., Lal, L. S., Essien, E. J., & Sansgiry, S. S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2061260 · Cited by 11
“This result is consistent with literature which emphasizes the importance of medication adherence and receiving appropriate medications among the T2D population [10,49].”
ResultSoliman, M. O., El-Kamel, A. H., Shehat, M. G., Bakr, B. A., & El‐Moslemany, R. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123551 · Cited by 11
Transfer of primary care patients receiving chronic care: the next step in the continuum of care
Odayar, J., & Myer, L. (2019) · International Health · doi:10.1093/inthealth/ihz014 · Cited by 11
Effect of Bay Leaf Ethanol Extract on Blood Glucose Level in Patients with Type 2 Diabetes Mellitus
Widyawati, T., Pase, M. A., Daulay, M., et al. (2019) · Strengthening Hospital Competitiveness to Improve Patient Satisfaction and Better Health Outcomes · doi:10.26911/the6thicph-fp.05.07 · Cited by 9
“Long term treatment was also as an important issue that related to the patient adherence (Awodele and Osuolale, 2015; Polonsky and Henry, 2016).”
BackgroundSHELBAYA, M. D. M. H. S., & Nasr, M. (2020) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2020.110954 · Cited by 9
Qiu, Y., Chao, C.-Y., Jiang, L., Zhang, J., Niu, Q., Guo, Y., Song, Y., Li, P., Zhu, M., & Yin, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174796 · Cited by 9
Sinamaw, D., Getnet, M., Abdulkadir, M., Abebaw, K., Ebrahim, M., Diress, M., Akalu, Y., Ambelu, A., & Dagnew, B. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02661-2 · Cited by 12
“This difference might be due to adherence to diabetic medication, and self-glucose monitoring practice awareness creation for the patients [47].”
BackgroundCurrent analytical methods to monitor type 2 diabetes medication in biological samples
Rakusanova, S., & Čajka, T. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116831 · Cited by 10
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.